The FTC Finds that Authorized Generic Drugs Yield Procompetitive Benefits

September 07, 2011
The FTC recently announced its findings on the competitive effects of authorized generic drugs, which provided strong support for the conclusion that entry by authorized generic drugs is procompetitive because it lowers prescription drug prices without deterring traditional generic entry. The FTC may, however, challenge patent settlements involving authorized generic delay as they have patent settlements involving cash payments for generic delay. This update analyzes the FTC’s study and its findings.